Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.516
Filter
2.
In. Soeiro, Alexandre de Matos; Leal, Tatiana de Carvalho Andreucci Torres; Accorsi, Tarso Augusto Duenhas; Gualandro, Danielle Menosi; Oliveira Junior, Múcio Tavares de; Caramelli, Bruno; Kalil Filho, Roberto. Manual da residência em cardiologia / Manual residence in cardiology. Santana de Parnaíba, Manole, 2 ed; 2022. p.788-792, tab.
Monography in Portuguese | LILACS | ID: biblio-1353341
4.
Arq. bras. cardiol ; 117(2): 270-278, ago. 2021. tab, graf
Article in Portuguese | LILACS | ID: biblio-1339144

ABSTRACT

Resumo Fundamento: O uso de estatinas destaca-se como a terapia mais frequentemente utilizada para o tratamento de dislipidemias e pode ser considerado a intervenção farmacológica mais eficiente para a redução da lipoproteína de baixa densidade (LDL). Por outro lado, o treinamento físico pode ser considerado uma estratégia não farmacológica eficiente e segura para promover melhorias no perfil lipídico. No entanto, não se sabe qual seria a influência das estatinas nas adaptações lipídicas decorrentes do treinamento aquático em populações com dislipidemia. Objetivos: Analisar a influência do uso de sinvastatina nas adaptações lipídicas decorrentes do treinamento aeróbico em meio aquático e de resistência em mulheres idosas com dislipidemia. Métodos: Sessenta e nove mulheres idosas (66,13 ± 5,13 anos), sedentárias e dislipidêmicas, tanto não usuárias quanto usuárias de sinvastatina (20 mg e 40 mg), foram randomizadas nos 3 grupos seguintes: treinamento aeróbico em meio aquático (WA), treinamento de força em meio aquático (WR) e grupo controle (GC). A duração total das intervenções, para todos os grupos experimentais, foi de 10 semanas, com 2 sessões semanais. As análises bioquímicas foram realizadas antes do início das intervenções e repetidas após o final do ensaio. Foram utilizadas equações de estimativa generalizada para comparar esses dados, estabelecendo α = 0,05. Resultados: Na análise por intenção de tratar, as participantes medicadas demonstraram uma redução de magnitude maior do colesterol total (CT) (−3,41 a −25,89 mg.dl−1; p = 0,038), LDL (−5,58 a −25,18 mg.dl−1; p = 0,007) e da relação CT/HDL (−0,37 a −0,61; p = 0,022) quando comparadas às participantes não medicadas, essa redução sendo estatisticamente significativa apenas no grupo WR. Conclusões: O uso de estatina incrementa as adaptações promovidas pelo treinamento físico aquático no CT, nos níveis de LDL e na relação CT/HDL, sendo mais pronunciado após WR.


Abstract Background: Statin use is highlighted as the most commonly utilized therapy for the treatment of dyslipidemias and can be considered as the most efficient pharmacological intervention for low-density lipoprotein (LDL) reduction. On the other hand, physical training can be considered an efficient and safe non-pharmacological strategy to promote improvements in lipid profile. However, the influence of statins on lipid adaptations arising from water-based training in populations with dyslipidemia is not known. Objectives: To analyze the influence of simvastatin use on lipid adaptations arising from water-based aerobics and resistance training in elderly women with dyslipidemia. Methods: Sixty-nine elderly (66.13 ± 5.13 years), sedentary, and dyslipidemic women, both non-users and users of simvastatin (20 mg and 40 mg), were randomized into the following 3 groups: water-based aerobic training (WA), water-based resistance training (WR), and control group (CG). Total duration of interventions, for all experimental groups consisted of 10 weeks, with 2 weekly sessions. Biochemical analyses were performed before the beginning of the interventions and repeated after the end of the trial. Generalized estimating equations were used to compare these data, setting α = 0.05. Results: In intention-to-treat analysis, the medicated participants obtained a greater magnitude of decrease in total cholesterol (TC) (−3.41 to −25.89 mg.dl−1; p = 0.038), LDL (−5.58 to −25.18 mg.dl−1; p = 0.007) and TC/HDL ratio (−0.37 to −0.61; p = 0.022) when compared to the non-medicated participants, and this decrease was statistically significant only in the WR group. Conclusions: Statin use enhances the adaptations promoted by water-based physical training in CT, LDL levels, and CT/HDL ratio, and it is more pronounced after WR.


Subject(s)
Humans , Female , Aged , Cardiovascular Diseases , Dyslipidemias/drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Cholesterol, HDL , Cholesterol, LDL
5.
Arq. bras. cardiol ; 116(4): 706-712, abr. 2021. tab, graf
Article in Portuguese | LILACS | ID: biblio-1285185

ABSTRACT

Resumo Fundamento Indivíduos com hipercolesterolemia grave apresentam alto risco de desenvolver doença cardiovascular aterosclerótica (DCVA). Muitos deles apresentam hipercolesterolemia familiar (HF). Objetivos Avaliar, a partir da perspectiva dos pacientes, o nível de conhecimento sobre a hipercolesterolemia grave, especialmente em relação a HF, DCVA, percepção de risco, desempenho do rastreamento em cascata e tratamento de indivíduos participantes de um programa de avaliação periódica de saúde. Métodos De um banco de dados de 70.000 brasileiros avaliados entre 2006 e 2016, 1.987 (2,8%) atenderam aos critérios de inclusão (idade ≥ 18 anos e LDL-C ≥ 190 mg/dL ou ≥ 160 mg/dL se sem uso de estatinas ou em terapia com estatinas, respectivamente). Desses, 200 foram aleatoriamente convidados a preencher um questionário extenso. A HF foi diagnosticada em caso de suspeita pelo médico responsável. Resultados Embora 97% da amostra (48±9 anos; 16% do sexo feminino; 95% com ensino superior; 88% em prevenção primária; LDL-C 209±47 mg/dL) tenha apresentado hipercolesterolemia grave, apenas 18% e 29,5% se consideravam de alto risco para desenvolver DCVA e relataram saber sua meta recomendada de LDL-C, respectivamente. Em relação à possibilidade de o colesterol alto ser uma doença hereditária, 58% relataram conhecimento sobre o fato; 24,5% (n = 49) já tinham ouvido falar em HF; e apenas 14% (n = 20) foram previamente identificados com suspeita de HF (idade ao diagnóstico de HF: 35±12 anos; 79% e 31% foram diagnosticados com > 30 e > 40 anos, respectivamente). Apenas 2,5% foram submetidos a testes genéticos; 17%, à rastreamento em cascata; e 17% não faziam uso de tratamento farmacológico. Conclusões Identificou-se uma importante lacuna na percepção de risco, no controle do colesterol e em aspectos relacionados à HF em indivíduos com hipercolesterolemia grave. (Arq Bras Cardiol. 2021; [online].ahead print, PP.0-0)


Abstract Background Individuals with severe hypercholesterolemia are at a high risk of developing atherosclerotic cardiovascular disease (ASCVD). Many of them have familial hypercholesterolemia (FH). Objectives To assess from a patient perspective the degree of awareness about severe hypercholesterolemia, especially FH, ASCVD risk perception, cascade screening performance, and treatment of individuals participating in a routine health evaluation program. Methods From a database of 70,000 Brazilian individuals evaluated between 2006 and 2016, 1,987 (2.8%) met the inclusion criteria (age ≥ 18 years and LDL-C ≥ 190 mg/dL or ≥ 160 mg/dL, respectively, if not in use of statins or on statin therapy). Two-hundred individuals were randomly invited to complete an extensive questionnaire. FH was diagnosed if suspected by the attending physician. Results Although 97% of the sample (age 48±9 years; 16% women; 95% college/university education; 88% primary prevention; LDL-C 209±47 mg/dL) had severe hypercholesterolemia, only 18% and 29.5% believed to be at high ASCVD risk and reported knowledge of their recommended LDL-C goal, respectively. Fifty-eight percent reported being informed that high cholesterol could be a family disease, 24.5% (n = 49) had ever heard about FH, and merely 14% (n = 29) had been previously identified as suspected of having FH (age at FH diagnosis 35±12 years; 79% and 31% diagnosed, respectively, > 30 and > 40 years old). Only 2.5% underwent genetic tests, 17% underwent cascade screening, and 17% were not in use of pharmacological treatment. Conclusions An important gap in risk perception, cholesterol management, and aspects related to FH was encountered in individuals with severe hypercholesterolemia. (Arq Bras Cardiol. 2021; [online].ahead print, PP.0-0)


Subject(s)
Humans , Male , Female , Adolescent , Adult , Cardiovascular Diseases/etiology , Cardiovascular Diseases/prevention & control , Hypercholesterolemia/drug therapy , Hyperlipoproteinemia Type II/drug therapy , Brazil , Risk Factors , Heart Disease Risk Factors , Cholesterol, LDL , Middle Aged
6.
Rev. ecuat. pediatr ; 22(1): 1-10, Abril 30, 2021.
Article in English | LILACS | ID: biblio-1222381

ABSTRACT

Introducción: La hipercolesterolemia familiar (HF) un trastorno genético autosómico domi-nante que produce un desarrollo prematuro de enfermedades cardiovasculares. Las estati-nas han sido el medicamento de elección en estos pacientes, sin embargo, un buen por-centaje de pacientes no pueden alcanzar sus objetivos terapéuticas con las dosis máximas por lo que la Lomitapida se podría establecer como una nueva alternativa de tratamiento. Objetivo: El objetivo de esta revisión sistemática es determinar si la Lomitapida reduce los eventos cardiovasculares en pacientes con diagnóstico de Hipercolesterolemia familiar comparado con estatinas. Métodos: Se incluirán ensayos controlados aleatorios (ECA) y cuasialeatorios de pacientes con diagnóstico de HF. Las medidas de resultado los niveles de LDL, HDL pos tratamiento y eventos cardiovasculares. Las búsquedas electrónicas se realizarán en PUBMED, The Coch-rane Central Register of Controlled Trials (CENTRAL), EMBASE y Scientific electronic library (Scielo). En la evaluación del riesgo de sesgo se utilizará la herramienta de Cochrane. Las medidas del efecto del tratamiento serán las diferencias de medias (DM) y los intervalos de confianza (IC) del 95%. La evaluación de heterogeneidad se realizará mediante la inspec-ción visual del diagrama de embudo. La evaluación de la calidad de la evidencia se reali-zará usando la evaluación GRADE.


Introduction: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disor-der that produces hypercholesterolemia and premature development of cardiovascular diseas-es. Statins are the drug of choice in these patients; however, a high percentage of patients cannot achieve their therapeutic goals with the maximum recommended doses, so Lo-mitapide may prove to be useful as a new treatment alternative to traditional statins. Objective: The objective of this systematic review is to determine if Lomitapide is better than statins at reducing cardiovascular events in patients with a diagnosis of FH. Methods: Randomized controlled trials (RCTs) and quasi-randomized trials of patients di-agnosed with FH will be included. Primary outcome measures included several parameters: 1. Post-treatment low- and high-density lipoprotein (LDL and HDL, respectively) levels and 2. Presence of cardiovascular events. Electronic searches will be conducted in PUBMED, The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, and the scientific elec-tronic library (Scielo). The assessment of the risk of bias will be used by the Cochrane tool. The measures of the treatment effect will be considered the mean differences (MD) and the 95% confidence intervals (CI). The evaluation of heterogeneity will be done by visual inspec-tion of the funnel diagram. The evaluation of the quality of the evidence will be done using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) ap-proach.


Subject(s)
Cardiovascular Diseases , Systematic Review , Hydroxymethylglutaryl CoA Reductases , Lipoproteins, LDL , Protocols , Hypercholesterolemia , Cholesterol, LDL , Anticholesteremic Agents
7.
Rev. ecuat. pediatr ; 22(1): 1-10, Abril 30, 2021.
Article in English | LILACS | ID: biblio-1222382

ABSTRACT

Introducción: La hipercolesterolemia familiar (HF) un trastorno genético autosómico domi-nante que produce un desarrollo prematuro de enfermedades cardiovasculares. Las estati-nas han sido el medicamento de elección en estos pacientes, sin embargo, un buen por-centaje de pacientes no pueden alcanzar sus objetivos terapéuticas con las dosis máximas por lo que la Lomitapida se podría establecer como una nueva alternativa de tratamiento. Objetivo: El objetivo de esta revisión sistemática es determinar si la Lomitapida reduce los eventos cardiovasculares en pacientes con diagnóstico de Hipercolesterolemia familiar comparado con estatinas. Métodos: Se incluirán ensayos controlados aleatorios (ECA) y cuasialeatorios de pacientes con diagnóstico de HF. Las medidas de resultado los niveles de LDL, HDL pos tratamiento y eventos cardiovasculares. Las búsquedas electrónicas se realizarán en PUBMED, The Coch-rane Central Register of Controlled Trials (CENTRAL), EMBASE y Scientific electronic library (Scielo). En la evaluación del riesgo de sesgo se utilizará la herramienta de Cochrane. Las medidas del efecto del tratamiento serán las diferencias de medias (DM) y los intervalos de confianza (IC) del 95%. La evaluación de heterogeneidad se realizará mediante la inspec-ción visual del diagrama de embudo. La evaluación de la calidad de la evidencia se reali-zará usando la evaluación GRADE.


Introduction: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disor-der that produces hypercholesterolemia and premature development of cardiovascular diseas-es. Statins are the drug of choice in these patients; however, a high percentage of patients cannot achieve their therapeutic goals with the maximum recommended doses, so Lo-mitapide may prove to be useful as a new treatment alternative to traditional statins. Objective: The objective of this systematic review is to determine if Lomitapide is better than statins at reducing cardiovascular events in patients with a diagnosis of FH. Methods: Randomized controlled trials (RCTs) and quasi-randomized trials of patients di-agnosed with FH will be included. Primary outcome measures included several parameters: 1. Post-treatment low- and high-density lipoprotein (LDL and HDL, respectively) levels and 2. Presence of cardiovascular events. Electronic searches will be conducted in PUBMED, The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, and the scientific elec-tronic library (Scielo). The assessment of the risk of bias will be used by the Cochrane tool. The measures of the treatment effect will be considered the mean differences (MD) and the 95% confidence intervals (CI). The evaluation of heterogeneity will be done by visual inspec-tion of the funnel diagram. The evaluation of the quality of the evidence will be done using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) ap-proach.


Subject(s)
Cardiovascular Diseases , Systematic Review , Hydroxymethylglutaryl CoA Reductases , Lipoproteins, LDL , Protocols , Hypercholesterolemia , Cholesterol, LDL , Anticholesteremic Agents
8.
Rev. ecuat. pediatr ; 22(1): 1-10, Abril 30, 2021.
Article in English | LILACS | ID: biblio-1222385

ABSTRACT

Introducción: La hipercolesterolemia familiar (HF) un trastorno genético autosómico domi-nante que produce un desarrollo prematuro de enfermedades cardiovasculares. Las estati-nas han sido el medicamento de elección en estos pacientes, sin embargo, un buen por-centaje de pacientes no pueden alcanzar sus objetivos terapéuticas con las dosis máximas por lo que la Lomitapida se podría establecer como una nueva alternativa de tratamiento. Objetivo: El objetivo de esta revisión sistemática es determinar si la Lomitapida reduce los eventos cardiovasculares en pacientes con diagnóstico de Hipercolesterolemia familiar comparado con estatinas. Métodos: Se incluirán ensayos controlados aleatorios (ECA) y cuasialeatorios de pacientes con diagnóstico de HF. Las medidas de resultado los niveles de LDL, HDL pos tratamiento y eventos cardiovasculares. Las búsquedas electrónicas se realizarán en PUBMED, The Coch-rane Central Register of Controlled Trials (CENTRAL), EMBASE y Scientific electronic library (Scielo). En la evaluación del riesgo de sesgo se utilizará la herramienta de Cochrane. Las medidas del efecto del tratamiento serán las diferencias de medias (DM) y los intervalos de confianza (IC) del 95%. La evaluación de heterogeneidad se realizará mediante la inspec-ción visual del diagrama de embudo. La evaluación de la calidad de la evidencia se reali-zará usando la evaluación GRADE.


Introduction: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disor-der that produces hypercholesterolemia and premature development of cardiovascular diseas-es. Statins are the drug of choice in these patients; however, a high percentage of patients cannot achieve their therapeutic goals with the maximum recommended doses, so Lo-mitapide may prove to be useful as a new treatment alternative to traditional statins. Objective: The objective of this systematic review is to determine if Lomitapide is better than statins at reducing cardiovascular events in patients with a diagnosis of FH. Methods: Randomized controlled trials (RCTs) and quasi-randomized trials of patients di-agnosed with FH will be included. Primary outcome measures included several parameters: 1. Post-treatment low- and high-density lipoprotein (LDL and HDL, respectively) levels and 2. Presence of cardiovascular events. Electronic searches will be conducted in PUBMED, The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, and the scientific elec-tronic library (Scielo). The assessment of the risk of bias will be used by the Cochrane tool. The measures of the treatment effect will be considered the mean differences (MD) and the 95% confidence intervals (CI). The evaluation of heterogeneity will be done by visual inspec-tion of the funnel diagram. The evaluation of the quality of the evidence will be done using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) ap-proach.


Subject(s)
Cardiovascular Diseases , Systematic Review , Hydroxymethylglutaryl CoA Reductases , Lipoproteins, LDL , Protocols , Hypercholesterolemia , Cholesterol, LDL , Anticholesteremic Agents
9.
Arq. ciências saúde UNIPAR ; 25(1): 43-51, jan-abr. 2021.
Article in Portuguese | LILACS | ID: biblio-1151409

ABSTRACT

Introdução: Usuários do sistema de saúde com doenças crônicas não transmissíveis devem estar em acompanhamento constante para evitar complicações em seu estado de saúde. Objetivo: Analisar os indicadores laboratoriais de saúde em usuários de uma Unidade Básica de Saúde com e sem o diagnóstico para a diabetes e hipertensão. Métodos: A amostra foi de 231 usuários de uma unidade básica de saúde da cidade de Santarém-PA, maiores de idade, que foram agrupados em pacientes com DM/HAS (DM/HAS; n=144), e sem o diagnóstico para DM/HAS (AUS; n=87). As coletas envolveram informações socioeconômicas, clínicas e laboratoriais. Os dados foram tratados com estatística descritiva e inferencial, adotando-se p<0.05. Resultados: Tanto no DM/HAS como no AUS predominou o sexo feminino, estado civil casado, com vínculo empregatício, cor de pele parda, com 4-7 anos de estudo, renda de 1-2 salários, não tabagistas, não etilista e faixa etária de 38-77 anos. A HAS foi a doença mais presente de forma geral, bem como por sexo. Identificou-se no DM/HAS valores menores para a taxa de filtração glomerular (TFG) e maiores valores para a glicemia, triglicerídeos, colesterol total, LDL-c e não HDL-c. Conclusão: De acordo com a proposta desenvolvida, destaca-se que os usuários com DM/HAS apresentam associação positiva para valores alterados de glicemia, colesterol total, não HDL-c, triglicerídeos, TFG e para a presença da síndrome metabólica e risco cardiovascular moderado/alto.


Introduction: Users of the health system with chronic non-communicable diseases must be constantly monitored to avoid complications in their health status. Objective: Analyze laboratory health indicators in users of a Basic Health Unit with and without a diagnosis for diabetes and hypertension. Methods: The sample consisted of 231 users of a basic health unit in the city of Santarém-PA, all of them of age, grouped into patients with DM/SAH (DM/SAH; n=144), and without the diagnosis for DM/SAH (ABS; n=87). The collections involved socioeconomic, clinical, and laboratory information. The data were treated with descriptive and inferential statistics, adopting p <0.05. Results: In both DM/SAH and ABS groups, there was a predominance of female individuals, married status, employed, brown skin color, with 4-7 years of study, income of 1-2 salaries, non-smokers, non-alcoholic drinkers, and aged between 38-77 years. SAH was the most common disease in general, as well as when analyzing by gender. Lower values for the glomerular filtration rate (GFR) were identified in the DM/SAH and higher values for the glycemia, triglycerides, total cholesterol, LDL-c, and non-HDL-c. Conclusion: According to the proposal of this paper, it is noteworthy that users with DM/SAH have a positive association for altered values of blood glucose, total cholesterol, non-HDL-c, triglycerides, GFR, and for the presence of metabolic syndrome and moderate/high cardiovascular risk.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Health Evaluation/statistics & numerical data , Health Centers , Health Status Indicators , Tobacco Use Disorder/complications , Triglycerides/blood , Blood Glucose , Alcohol Drinking/adverse effects , Cardiovascular Diseases/diagnosis , Cholesterol/blood , Chronic Disease/nursing , Metabolic Syndrome/diagnosis , Diabetes Mellitus/diagnosis , Noncommunicable Diseases/prevention & control , Glomerular Filtration Rate , Hypertension/diagnosis , Cholesterol, HDL , Cholesterol, LDL/blood
10.
Rev. chil. endocrinol. diabetes ; 14(2): 59-64, 2021. tab, ilus
Article in Spanish | LILACS | ID: biblio-1283550

ABSTRACT

INTRODUCCIÓN: El hipotiroidismo subclínico (HSC) se define bioquímicamente por una elevación en la concentración sérica de la hormona estimulante de la tiroides (TSH), con niveles normales de tiroxina libre (T4L). La asociación entre el HSC y el daño cardiovascular ha sido un tema controversial. OBJETIVO: determinar la asociación entre el HSC y el desarrollo de la enfermedad cardiovascular mediante la cuantificación de la proteína C reactiva ultrasensible PCR-us y la determinación de lípidos circulantes asociados a la enfermedad cardiovascular y la ateroesclerosis. MÉTODOS: Estudio descriptivo, correlacional de corte transversal realizado en el Hospital IESS de Riobamba, Ecuador en el periodo comprendido desde enero a diciembre de 2019. Se estudiaron 70 individuos (40 pacientes con HSC y 30 controles) con edades entre 18 y 75 años. Se realizaron las historias clínicas y el examen físico a cada paciente y la toma de las muestras sanguíneas para determinar la concentración sérica de los siguientes parámetros bioquímicos y hormonales: colesterol total, triglicéridos, HDL colesterol y LDL colesterol, TSH, T4L y PCR-us. RESULTADOS: Se encontró un incremento significativo en la concentración de colesterol total (p<0.0001), LDL colesterol (p<0.01) y PCR-us (p<0.0001) en los pacientes con HSC vs los controles. Se observó una correlación positiva (p<0.0001; r=0.9148) entre la TSH y la PCR-us en los pacientes con HSC. CONCLUSIÓN: los pacientes con HSC experimentan una elevación en los niveles séricos de PCR-us la cual está correlacionada con un incremento en la concentración sérica de TSH. Estos parámetros asociados a un aumento del colesterol total y de la LDL colesterol sugieren un estado inflamatorio de bajo grado que podría estar asociado con el desarrollo de aterosclerosis y daño cardiovascular.


INTRODUCTION: Subclinical hypothyroidism (SH) is defined biochemically by an elevation in serum thyroid stimulating hormone (TSH) concentration, with normal levels of free thyroxine (T4L). The association between SH and cardiovascular damage has been a controversial issue. OBJECTIVE: to determine the association between SH and the development of cardiovascular disease through the quantification of the high sensitivity C-reactive protein (hs-PCR) and the determination of circulating lipids associated to cardiovascular disease and atherosclerosis. METHODS: Observational, correlational cross-sectional study with patients captured in the internal medicine office as well as those attending screening activities at the IESS Hospital in Riobamba- Ecuador, in the period from January to December 2019. Seventy individuals (40 patients with SH and 30 controls) between the ages of 18 and 75 years were studied. Each patient's medical history and physical examination were performed, and blood samples were taken to determine the serum concentration of the following biochemical and hormonal parameters: total cholesterol, triglycerides, HDL cholesterol and LDL cholesterol, TSH, T4L and hs-PCR. RESULTS: A significant increase in the concentration of total cholesterol (p<0.0001), LDL cholesterol (p<0.01) and hs-PCR (p<0.0001) was found in patients with SH vs. controls. A positive correlation (p<0.0001; r=0.9148) was observed between TSH and hs-PCR in patients with SH. CONCLUSION: patients with SH experience an elevation in serum hs-PCR levels which is correlated with an increase in serum TSH concentration. These parameters associated with an increase in total cholesterol and LDL cholesterol suggest a low-grade inflammatory state that may be associated with the development of atherosclerosis and cardiovascular damage.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Young Adult , C-Reactive Protein/analysis , Cardiovascular Diseases/etiology , Hypothyroidism/blood , Thyrotropin/blood , Body Mass Index , Cross-Sectional Studies , Ecuador , Atherosclerosis , Hypothyroidism/complications , Cholesterol, HDL/blood , Cholesterol, LDL/blood
11.
Rev. chil. endocrinol. diabetes ; 14(2): 65-73, 2021. tab, ilus
Article in Spanish | LILACS | ID: biblio-1283551

ABSTRACT

INTRODUCCIÓN: Las dislipidemias favorecen la formación precoz de placas ateroscleróticas, aumentando el riesgo de enfermedades cardiovasculares (ECVs). La Actividad Física (AF) es un factor protector de ECVs, por lo que el objetivo de este trabajo fue evaluar la asociación entre AF medida objetivamente y dislipidemias en población pediátrica. METODOLOGÍA: La AF fue evaluada en 159 niños (9-13 años) de la Región de La Araucanía a través de acelerometría (ActiGraph GT3X+). Por este medio se estimó el porcentaje de AF moderada a vigorosa (AFMV) y el de conducta sedentaria (CS). Sujetos con ≥60 min de AFMV se consideraron físicamente activos según recomendación de la Organización Mundial de la Salud (OMS). Individuos con %CS>75° percentil fueron considerados sedentarios. El perfil lipídico fue determinado usando métodos convencionales. Fueron calculados índices de aterogenicidad TG/cHDL e índice de aterogenicidad del plasma (IAP). RESULTADOS: 37,1% presentó dislipidemia, 8% hipercolesterolemia, 19,5% hipertrigliceridemia, 6,3% cLDL elevado y 25,2% cHDL disminuido. Solo un 9,4% fueron considerados físicamente activos de acuerdo a la recomendación de la OMS. En los sujetos físicamente activos no hubo caso de dislipidemias (p= 0,032) y tampoco bajos niveles de cHDL (p= 0,013). El %AFMV estaba reducido en sujetos con cHDL bajo y se correlacionó positivamente con HDL-c (r= 0,157, p=0,048). Además, el %AFMV se correlacionó con menores valores de TG/cHDL (r= -0,193, p=0,015) e IAP (r= -0,214, p=0,006). Si bien el comportamiento sedentario no estuvo asociado con riesgo de dislipidemias, el %CS se correlacionó positivamente con niveles de glucosa (r= 0,159, p=0,044) y HOMA-IR (r= 0,178, p=0,037) y negativamente con Quicki (r= -0,160, p=0,044). CONCLUSIONES: Los hallazgos sugieren que la AF se correlaciona a menor frecuencia de dislipidemias y la práctica de AFMV aumentaría los valores de HDL-c y reduciría los índices aterogénicos, por lo que promoverla puede significar disminuir el riesgo de ECVs en nuestra población. Además, la CS se relaciona con un aumento en valores de glucosa e índices de resistencia insulínica en escolares de la Región de La Araucanía.


Dyslipidemias cause early formation of atherosclerotic plaque, increasing the risk of cardiovascular diseases (CVD). Physical Activity (PA) is a protective factor against CVDs. The aim of this study is to evaluate the association between objectively measured PA with dyslipidemias in a pediatric population. METHOD: The PA was evaluated in 159 children (9-13 years old) from Región de La Araucanía using accelerometry (ActiGraph GT3X +). The percentage of moderate to vigorous PA (MVPA) and sedentary behavior (SB) were estimated. Subjects with ≥60 min of MVPA were considered physically active according to the recommendation of the World Health Organization (WHO). Individuals with %SB >75th percentile were sedentary. The lipid profile was determined using conventional methods. TG/HDL-C ratio and atherogenic index of plasma (AIP) were calculated. RESULTS: 37.1% presented dyslipidemia, 8% hypercholesterolemia, 19.5% hypertriglyceridemia, 6.3% elevated LDL-C and 25.2% decreased HDL-C. Only 9.4% were physically active according to the WHO recommendation. In physically active subjects where no cases of dyslipidemias (p =0.032) and no low HDL-C (p = 0.013). The %MVPA was reduced in subjects with low HDL-C and positively correlated with HDL-c (r = 0.157, p = 0.048). In addition, %MVPA was correlated with lower TG / HDL-C values (r = -0.193, p = 0.015) and AIP (r = -0.214, p = 0.006). SB was not associated with risk of dyslipidemia, % SB was positively correlated with glucose levels (r = 0.159, p = 0.044) and HOMA-IR (r = 0.178, p = 0.037) and negatively with Quicki (r = -0.160, p = 0.044). CONCLUSIONS: Our results suggested that PA is it correlates to a lower frequency of dyslipidemia and the practice of MVPA would increase HDL-c values and reduce atherogenic index, promoting it may been reducing the risk of CVDs in our population. In addition, the SB is related to an increase in glucose values and insulin resistance index in schoolchildren in Región de La Araucanía.


Subject(s)
Humans , Male , Female , Child , Adolescent , Cardiovascular Diseases/prevention & control , Exercise , Dyslipidemias/blood , Students , Triglycerides/blood , Body Weight , Insulin Resistance , Chile , Anthropometry , Nutritional Status , Cross-Sectional Studies , Education, Primary and Secondary , Atherosclerosis/blood , Sedentary Behavior , Accelerometry , Heart Disease Risk Factors , Homeostasis , Cholesterol, HDL/blood , Cholesterol, LDL/blood
12.
Rev. colomb. cardiol ; 27(6): 511-516, nov.-dic. 2020. tab, graf
Article in Spanish | LILACS, COLNAL | ID: biblio-1289266

ABSTRACT

Resumen Introducción: Los pacientes con enfermedad aterosclerótica establecida requieren tratamiento con estatinas para reducir la probabilidad de nuevos eventos. Objetivo: Identificar el porcentaje de pacientes con enfermedad coronaria aterosclerótica establecida que logran niveles de cLDL (colesterol LDL) inferiores a 70mg/dl y describir su distribución en tres grupos terapéuticos: estatinas, otros hipolipemiantes y sin tratamiento. Métodos: Estudio observacional descriptivo de corte transversal, en el que se seleccionaron pacientes de tres hospitales de alta complejidad, mayores de 18 años, con enfermedad aterosclerótica diagnosticada a partir del año 2017. El registro del perfil lipídico corresponde al realizado al menos tres meses después del diagnóstico. Resultados: Se incluyeron en total 746 pacientes con enfermedad coronaria aterosclerótica, con un promedio de edad de 65,3±10,9 años y predominio del sexo masculino (75,5%). Del total de los pacientes evaluados se prescribieron un 97,8% de terapia con al menos una estatina, 0,7% de otros hipolipemiantes y 1,5% no presentaron tratamiento. Los pacientes con niveles de cLDL inferior a 70mg/dl corresponden al 56%. Conclusiones: La extensa divulgación de guías de práctica clínica para dislipidemias en adultos en Colombia, y la incorporación de estatinas de alta intensidad, demuestran una mejoría en la proporción del cumplimiento en metas de cLDL para pacientes con enfermedad aterosclerótica establecida. Sin embargo, una alta proporción aún persiste fuera de metas, lo cual constituye una oportunidad de optimización del uso de terapias disponibles y recientemente desarrolladas.


Abstract Introduction: Patients with established atherosclerotic disease require treatment with statins in order to reduce the probability of new events. Objective: To identify the percentage of patients with established atherosclerotic coronary disease that achieve cLDL (LDL - cholesterol) levels less than 70mg/dL, and to describe its distribution in three treatment groups: statins, other lipid lowering drugs, and without treatment. Methods: A cross-sectional, descriptive observational study was conducted on patients diagnosed with atherosclerotic disease from 2017 and over 18-years-old from 3 tertiary hospitals. A record was made of the lipid profile that was performed at least three months after the diagnosis. Results: A total of 746 patients with atherosclerotic coronary disease were included. The mean age was 65.3±10.9 years and the majority (75.5%) were males. Of the total number of patients evaluated, 97.8% were prescribed a therapy with at least one statin, 0.7% with other lipid-lowering drugs, and 1.5% had no treatment. Just over half (56%) of the patients had cLDL levels of less than 70mg/dL. Conclusions: The widespread use of clinical practice guidelines for dyslipidaemias in adults in Colombia, and the incorporation of high-intensity statins, has led to an improvement in the proportion of patients with established atherosclerotic disease achieving cLDL targets. However, a high percentage still does not reach the targets, which suggests a need for an improving of the use of available and recently developed therapies.


Subject(s)
Humans , Male , Female , Middle Aged , Cholesterol, LDL , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Plaque, Atherosclerotic , Heart Disease Risk Factors , Lipids
13.
Rev. colomb. cardiol ; 27(6): 501-510, nov.-dic. 2020. tab, graf
Article in Spanish | LILACS | ID: biblio-1289265

ABSTRACT

Resumen Introducción: La hipercolesterolemia familiar homocigótica (HFHo) se caracteriza por niveles muy elevados de cLDL y por enfermedad aterosclerótica temprana. Aunque la frecuencia es baja (1/300.000), las complicaciones son muy severas y pueden ser evitadas. Encontrar y tratar esta población de manera temprana podría reducir la mortalidad. Se describen 36 casos en Colombia, en donde se calcula que haya entre 160 y 200 casos. Resultados: Un total de 36 pacientes con fenotipo sugestivo de HFHo fueron identificados y tratados en un período de observación de cuatro años. La media de edad fue 27 años (24 mujeres). 34 pacientes tuvieron un puntaje según la Red de Clínicas de Lípidos de Holanda (RCLH) mayor de 8 (diagnóstico definitivo) y los restantes 2 tenían puntaje equivalente a diagnóstico probable. Un cuarto de los casos procedían de la costa norte colombiana. En las pruebas genéticas, 14 fueron homocigóticos verdaderos para mutación del gen que codifica para el receptor de LDL (LDLR), 12 heterocigóticos compuestos, 2 heterocigóticos dobles y uno autosómico recesivo (LDLRAP1); 5 pacientes fueron heterocigóticos simples (LDLR) y 2 pacientes no autorizaron la prueba. En los homocigóticos verdaderos, la variante más frecuente encontrada fue la c.11G>A. 14 pacientes cursaron con enfermedad coronaria, 9 con estenosis carotídea, 8 con estenosis aórtica y 2 tuvieron ataques cerebrovasculares (ACV). 34 pacientes recibían estatinas (24 rosuvastatina), 30 recibían ezetimibe, 2 recibían evolocumab y 20 recibían lomitapide (dosis promedio 12,7mg). Ninguno recibió aféresis de cLDL. Los medicamentos, en general, fueron bien tolerados y la reducción promedio de cLDL con la terapia fue de 533,7mg/dl a 245,1mg/dl (54%). Conclusiones: Todos los pacientes recibieron tratamiento hipolipemiante y se encontraron alteraciones genéticas diagnósticas en todos aquellos que autorizaron el examen. Los niveles elevados de cLDL conllevan tanto riesgo que el tratamiento debe establecerse aún sin conocer el diagnóstico genético.


Abstract Background: Homozygous familial hypercholesterolemia (HoFH) is characterized for very high levels of cLDL and early cardiovascular disease. Although incidence is low (1/300 000), complications are very severe and can be avoided. Finding and treating this population promptly could reduce mortality. We describe 36 cases in Colombia, where 160 to 200 cases are expected. Results: 36 patients with phenotype of HoHF were identified and treated in a follow-up of 4 years. The mean age was 27 years (24 women). 34 of them had at least 8 points in the FH Dutch Lipid Clinic Criteria (definitive diagnosis) and two had probable diagnosis. A quarter of the cases came from the Colombian North Coast. In molecular tests, 14 were true homozygous for LDLR, 12 were compound heterozygous for LDLR, 2 double heterozygous and one was autosomal recessive; 5 were heterozygous and 2 patients did not authorized genetic test. In true homozygous subjects, the most frequent variant was c.11G>A. 14 patients had coronary disease, 9 carotid stenosis, 8 aortic stenosis and 2 had stroke. 34 patients were on statins (25 rosuvastatin), 30 were receiving ezetimibe, 2 were receiving a PSCK9 inhibitor (evolocumab) and 20 were on lomitapide with mean doses of 12.7mg. None received lipoprotein apheresis. Medications were very well tolerated. Changes in cLDL after therapy was from 533.7 mg/dL to 245 mg/dL, (54%). Conclusions: Treatment was started in all patients. We found genetic mutations in all patients with genetic tests. The high levels of cLDL mean such a high risk that treatment must be started promptly, even without a genetic test.


Subject(s)
Humans , Male , Female , Adult , Hypercholesterolemia , Alleles , Genetics , Hyperlipoproteinemia Type II , Lipids , Cholesterol, LDL , Mutation
14.
Arq. bras. cardiol ; 115(3): 462-467, out. 2020. tab
Article in English, Portuguese | SES-SP, LILACS, SES-SP | ID: biblio-1131319

ABSTRACT

Resumo Fundamento O Diabetes Mellitus Tipo 2 (DMT2) é comum nos idosos, que também apresentam um nível elevado de fatores de risco para doenças cardiovasculares (DCVs), tais como dislipidemia. Entretanto, o papel da depressão nos pacientes com DMT2 e sua relação com fatores de risco para DCV são pouco estudados. Objetivo O objetivo do presente estudo foi investigar a relação entre sintomas depressivos (SDs) e fatores de risco cardiovascular conhecidos em idosos comunitários portadores de DMT2. Métodos Trata-se de um estudo transversal, no qual foram incluídos 85 idosos comunitários com DMT2. Os SDs foram avaliados através da Escala de Depressão Geriátrica de Yesavage, em versão reduzida (GDS-15). Os seguintes fatores de risco cardiovascular foram avaliados: pressão arterial sistólica (PAS) e diastólica (PAD), glicose plasmática em jejum (GPJ), perfil lipídico (triglicerídeos séricos (TG), colesterol total sérico (CT), colesterol sérico de lipoproteína de baixa densidade (LDL-C) e colesterol sérico de lipoproteína de baixa densidade (HDL-C)) e índice de massa corporal (IMC). A análise de regressão múltipla de Poisson foi utilizada para avaliar a associação entre os SDs e cada fator de risco cardiovascular ajustado por sexo, idade, tempo em atividades físicas moderadas e status funcional. O nível de significância adotado para a análise foi de 5%. Resultados Dentre todos os fatores de risco analisados, apenas o aumento de LDL-C apresentou uma correlação com níveis elevados de SD (RP=1,005; IC95% 1,002-1,008). Foi observada uma associação significativa entre os níveis de HDL-C (RP=0,99; IC95% 0,98-0,99) e a PAS (RP=1,009; IC95% 1,004-1,014). Conclusão Nos idosos com DMT2, a presença de SD foi associada a níveis de LDL-C, HDL-C e PAS, mesmo após o ajuste por sexo, idade, nível de atividade física e capacidade funcional. (Arq Bras Cardiol. 2020; [online].ahead print, PP.0-0)


Abstract Background Type 2 Diabetes Mellitus (T2DM) is common in older adults, who also present a high level of risk factors for cardiovascular disease (CVD), such as dyslipidemia. However, the role of depression in T2DM patients and its relationship with CVD risk factors are understudied. Objective The present study aimed to investigate the relationship between depressive symptoms (DS) and known cardiovascular risk factors in community dwelling older adults with T2DM. Methods This is a cross sectional study, in which 85 community-dwelling older adults with T2DM were assessed. DS was assessed using the Yesavage Geriatric Depression Scale - short version (GDS-15). The following cardiovascular risk factors were evaluated: systolic (SBP) and diastolic blood pressure (DBP), fasting plasma glucose (FPG), lipid profile (serum triglycerides - TG, serum total cholesterol - TC, serum low-density lipoprotein cholesterol - LDL-C, and serum high-density lipoprotein cholesterol - HDL-C) and body mass index (BMI). Poisson multiple regression was performed to test the association between DS and each cardiovascular risk factor adjusted by sex, age, time spent in moderate physical activity, and functional status. The significance level adopted for the analysis was 5%. Results Among all the analyzed risk factors, only high levels of LDL-C were related to high DS (PR=1.005, CI 95% 1.002-1.008). A significant association was observed between HDL-C levels (PR=0.99, CI 95% 0.98-0.99) and SBP (PR=1.009, CI 95% 1.004-1.014). Conclusion In older adults with T2DM, the presence of DS was associated with LDL-C, HDL-C levels and SBP, even after adjusting for sex, age, physical activity level and functional capacity. (Arq Bras Cardiol. 2020; [online].ahead print, PP.0-0)


Subject(s)
Humans , Aged , Depression/etiology , Diabetes Mellitus, Type 2/complications , Triglycerides , Cross-Sectional Studies , Risk Factors , Cholesterol, HDL , Cholesterol, LDL
15.
Acta bioquím. clín. latinoam ; 54(3): 267-277, set. 2020. graf, tab
Article in Spanish | LILACS | ID: biblio-1130601

ABSTRACT

Diversos estudios evidencian la asociación entre los niveles elevados del colesterol de LDL (cLDL) y el riesgo de desarrollar enfermedad cardiovascular aterosclerótica. Con el objetivo de comparar los valores de cLDL obtenidos mediante la medición directa y los valores estimados por las ecuaciones de Friedewald tradicional, modificada y de regresión, se valoró el cLDL de 4.621 pacientes mediante el ensayo directo en el autoanalizador ADVIA 1800. Dichos resultados se agruparon en los estados de normolipemia, hipercolesterolemia, hiperlipemia mixta e hipertrigliceridemia y se establecieron diferencias de estimación con las mencionadas fórmulas en el total de la muestra y en los niveles de decisión clínica para el cLDL. Las tres fórmulas presentaron correlación significativa con el método directo en la totalidad de la muestra; sin embargo, cuando los niveles de triglicéridos de las muestras superaron los 200 mg/dL, la diferencia entre la fórmula de Friedewald y el método directo resultó -11,94%, y llegó a -19,13% para el nivel de triglicéridos mayor de 400 mg/dL. Por otro lado, las ecuaciones de Friedewald modificada y de regresión se vieron afectadas en menor cuantía por el nivel de triglicéridos. Las fórmulas de regresión y de Friedewald modificada se constituyen como alternativas razonables para estimar el cLDL y presentan buena concordancia con el método directo, incluso en niveles altos de colesterol y triglicéridos.


Several studies show the association between high LDL cholesterol (LDLc) levels and the risk of developing atherosclerotic cardiovascular disease. In order to compare the LDLc values obtained by direct measurement and the values estimated by the traditional, modified and regression Friedewald equations, the LDLc of 4,621 patients was assessed by means of the direct test in the ADVIA 1800 autoanalyzer.These results were grouped into the states of normolipemia, hypercholesterolemia, mixed hyperlipemia and hypertriglyceridemia, establishing differences in estimation with the aforementioned formulas in the total sample and in clinical decision levels for LDLc. The three formulas showed a significant correlation with the direct method in the entire sample; however, when the triglyceride levels of the samples exceeded 200 mg/dL, the difference between Friedewald's formula and the direct method was -11.94% reaching -19,13% for the triglyceride level greater than 400 mg/dL, while the modified Friedewald and regression equations were affected to a lesser extent by the triglyceride level. Regression and modified Friedewald formulas are constituted as reasonable alternatives to estimate LDLc and have good agreement with the direct method, even at high cholesterol and triglyceride levels.


Varios estudos evidenciam a associacao entre niveis elevados do colesterol LDL (cLDL) e o risco de desenvolver doenca cardiovascular aterosclerotica. Visando comparar os valores de cLDL obtidos atraves da medicao direta e os valores estimados pelas equacoes de Friedewald tradicional, modificada e de regressao, o cLDL de 4.621 pacientes foi avaliado por meio do teste direto no analisador automatico ADVIA 1800. Tais resultados foram agrupados nos estados de normolipemia, hipercolesterolemia, hiperlipemia mista e hipertrigliceridemia, estabelecendo-se diferencas na estimativa com as formulas mencionadas no total da amostra e nos niveis de decisao clinica para cLDL. As tres formulas apresentaram correlacao significativa com o metodo direto em toda a amostra, no entanto, quando os niveis de triglicerideos das amostras excederam 200 mg/dL, a diferenca entre a formula de Friedewald e o metodo direto foi de -11,94% atingindo -19,13% para o nivel de triglicerideos superior a 400 mg/dL. Por outra parte, as equacoes de Friedewald modificada e de regressao foram afetadas em menor grau pelo nivel de triglicerideos. As formulas de regressao e de Friedewald modificada se constituem como alternativas razoaveis para estimar o cLDL, e apresentam boa concordancia com o metodo direto, mesmo em niveis elevados de colesterol e triglicerideos.


Subject(s)
Triglycerides , Hypertriglyceridemia , Cholesterol , Hypercholesterolemia , Hyperlipidemias , Hyperlipoproteinemia Type V , Cholesterol, LDL , Cholesterol, LDL/blood , Patients , Association , Cardiovascular Diseases , Disease , Risk , Minors , Methods
16.
Rev. colomb. cardiol ; 27(4): 337-343, jul.-ago. 2020. graf
Article in Spanish | LILACS, COLNAL | ID: biblio-1289235

ABSTRACT

Resumen Introducción: El valor nutritivo de las proteínas derivadas de la carne magra de cerdo ha cambiado ostensiblemente con la tecnificación en la producción y la posibilidad de obtener productos que conserven un alto valor nutritivo. No obstante, en nuestro medio su consumo se ha estigmatizado por un posible aumento de riesgo cardiovascular. Objetivo: Evaluar el impacto del consumo de la carne magra de cerdo sobre algunos parámetros antropométricos y bioquímicos de riesgo cardiovascular. Métodos: Se realizó un estudio de seguimiento a un grupo de 47 personas sanas que consumieron 200 gramos de carne magra de cerdo durante un periodo de ocho semanas, durante las cuales se valoraron parámetros bioquímicos, antropométricos, nutricionales y de riesgo cardiovascular. Resultados: Se observó que, tanto a las cuatro como a las ocho semanas, los niveles de colesterol LDL y triglicéridos no variaron. No obstante, los niveles de colesterol HDL y los micronutrientes zinc, hierro y vitamina B12 aumentaron en plasma luego de ocho semanas de consumo de carne magra de cerdo. De igual forma, marcadores metabólicos, como la adiponectina y el IGF-1, incrementaron luego de ocho semanas de consumo. Conclusiones: De acuerdo con estas observaciones la carne magra de cerdo puede mejorar el aporte de algunos micronutrientes y parámetros metabólicos sin que se haya evidenciado un efecto adverso sobre ciertos parámetros de riesgo cardiovascular en individuos sanos.


Abstract Introduction: The nutritional value of proteins derived from lean pork meat has essentially changed with the introduction of technology in the production and the possibility of obtaining products that retain a high nutritional value. However, its consumption has been stigmatised in this country due to a possible increase in cardiovascular risk. Objective: To evaluate the impact of consuming lean pork meat on some anthropometric and biochemical parameters of cardiovascular risk. Methods: A follow-up study was conducted on a population of 47 healthy subjects that consumed 200 grammes of lean pork meat for a period of 8 weeks. An evaluation was made of some biochemical, anthropometric, nutritional and cardiovascular risk parameters. Results: No changes were observed in the LDL-cholesterol or triglyceride levels. However, the plasma levels of HDL-cholesterol, as well as those of micronutrients such as zinc, iron and vitamin B12, increased after 8 weeks of consuming lean pork meat. Furthermore, metabolic markers, like adiponectin and IGF-1, also increased after eight weeks of consumption. Conclusions: According to these observations, lean pork meat may improve the supply of some micronutrients, as well as some metabolic parameters, with no evidence of any adverse effects on certain cardiovascular risk factors in healthy individuals.


Subject(s)
Humans , Male , Female , Adult , Biochemical Phenomena , Anthropometry , Pork Meat , Heart Disease Risk Factors , Nutritional Physiological Phenomena , Vitamin B 12 , Cholesterol, HDL , Cholesterol, LDL
17.
Article in Spanish | LILACS, BDNPAR | ID: biblio-1293272

ABSTRACT

Numerosas investigaciones demuestran que existe alteración del metabolismo lipídico en pacientes con VIH/SIDA, caracterizada por un aumento en la concentración de triglicéridos y la disminución de las lipoproteínas de alta y baja densidad y del colesterol total. La dislipidemia en personas VIH/SIDA depende de la supresión viral en el momento del estudio, de la respuesta al agente antirretroviral específico que se relaciona con la susceptibilidad genética, además de otros factores entre los cuales se encuentra el empleo de medicamentos, el peso y el estilo de vida. Los pacientes que conviven con esta infección tienen por esta razón un riesgo incrementado de accidente cardiovascular y diabetes. El objetivo fue determinar si existían diferencias en el perfil lipídico en una cohorte de pacientes que reciben esquemas de tratamientos diferentes en la población enfocada. Este fue un diseño observacional de cohorte prospectivo (24) con componente analítico que incluyó pacientes con diagnóstico de HIV y con tratamiento que concurrieron al Programa Regional de Control VIH-SIDA en el Hospital Regional de Encarnación-VII Región Sanitaria de Itapúa de abril a septiembre de 2016. Se encontraron diferencias significativas en la mayoría de los analitos componentes del perfil lipídico. Es necesario realizar un control periódico del perfil lipídico en estos grupos de pacientes, pues ello contribuirá a un mejor seguimiento del estado de salud así como a la prevención de accidentes cardiovasculares en los pacientes que conviven con VIH/SIDA y que están en tratamiento con antirretrovirales


Numerous research studies show that there is an impaired lipid metabolism in patients with HIV/AIDS, characterized by an increase in triglyceride concentration and decreased high- and low-density lipoproteins and total cholesterol. Dyslipidemia in HIV/AIDS people depends on viral suppression at the time of the study, response to the specific antiretroviral agent that relates to genetic susceptibility, as well as other factors including the use of medications, weight and lifestyle. Therefore, patients living with this infection have an increased risk of cardiovascular accident and diabetes. The objective was to determine whether there were differences in lipid profile in a cohort of patients receiving different treatment schemes in the targeted population. This was a prospective cohort design research with analytical component that included patients with HIV diagnosis and treatment that attended the Regional HIV-AIDS Control Programme at the Regional Hospital of Encarnacion - VII Itapúa Health Region from April to September 2016. Significant differences were found in most analytes components of the lipid profile. A periodic control of the lipid profile is necessary in these patient groups as this will contribute to a better monitoring of the health status as well as to the prevention of cardiovascular accidents in patients living with HIV/AIDS, and who are being treated with antiretrovirals


Subject(s)
Humans , Male , Female , Acquired Immunodeficiency Syndrome/drug therapy , Anti-Retroviral Agents , Cholesterol, VLDL , Cholesterol , HIV , Cholesterol, LDL
18.
Arq. bras. cardiol ; 114(3): 469-475, mar. 2020. tab, graf
Article in English | LILACS | ID: biblio-1088903

ABSTRACT

Abstract Background: A sizeable proportion of patients have discordant low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). Objectives: We assessed the relationship between discordance of LDL-C and non-HDL-C and coronary artery disease (CAD) severity. Methods: We retrospectively evaluated the data of 574 consecutive patients who underwent coronary angiography. Fasting serum lipid profiles were recorded, SYNTAX and Gensini scores were calculated to establish CAD complexity and severity. We determined the medians for LDL-C and non-HDL-C to examine the discordance between LDL-C and non-HDL-C. Discordance was defined as LDL-C greater than or equal to the median and non-HDL-C less than median; or LDL-C less than median and non-HDL-C greater than or equal to median. A p value < 0.05 was accepted as statistically significant. Results: LDL-C levels were strongly and positively correlated with non-HDL-C levels (r = 0.865, p < 0.001) but 15% of patients had discordance between LDL-C and non-HDL-C. The percentage of patients with a Gensini score of zero or SYNTAX score of zero did not differ between discordant or concordant groups (p = 0.837, p = 0.821, respectively). Mean Gensini and SYNTAX scores, percentage of patients with Gensini score ≥20 and SYNTAX score >22 were not different from group to group (p = 0.635, p = 0.733, p = 0.799, p = 0.891, respectively). Also, there was no statistically significant correlation between LDL-C and Gensini or SYNTAX scores in any of the discordant or concordant groups. Additionally, no correlation was found between non-HDL-C and Gensini or SYNTAX score. Conclusions: While there was discordance between LDL-C and non-HDL-C (15% of patients), there is no difference regarding CAD severity and complexity between discordant and concordant groups.


Resumo Fundamento: Uma proporção considerável de pacientes apresenta níveis discordantes de colesterol de lipoproteína de baixa densidade (LDL) e de não alta densidade (não HDL). Objetivos: Avaliar a relação da discordância entre colesterol LDL e não HDL com a gravidade da doença arterial coronariana (DAC). Métodos: Avaliamos retrospectivamente os dados de 574 pacientes submetidos consecutivamente à angiografia coronariana. Foram registrados os perfis lipídicos séricos em jejum, e depois foram calculados os escores SYNTAX e Gensini para estabelecer a complexidade e a gravidade da DAC. Determinamos as medianas para colesterol LDL e não-HDL para examinar a discordância entre ambos. Discordância foi definida como LDL maior ou igual à mediana e não-HDL menor que mediana; ou LDL menor que a mediana e não-HDL maior ou igual à mediana. Valor de p < 0,05 foi aceito como estatisticamente significante. Resultados: Os níveis de colesterol LDL estiveram forte e positivamente correlacionados com os níveis de colesterol não-HDL (r = 0,865, p < 0,001), mas 15% dos pacientes apresentaram discordância entre LDL e não-HDL. A porcentagem de pacientes com escore Gensini ou SYNTAX zero não diferiu entre os grupos discordantes ou concordantes (p = 0,837, p = 0,821, respectivamente). Escores médios de Gensini e SYNTAX, porcentagem de pacientes com escore Gensini ≥ 20 e SYNTAX > 22 não foram diferentes de grupo para grupo (p = 0,635, p = 0,733, p = 0,799, p = 0,891, respectivamente). Além disso, não houve correlação estatisticamente significativa entre os escores de cholesterol LDL e Gensini ou SYNTAX em nenhum dos grupos discordantes ou concordantes. Também não foi encontrada correlação entre cholesterol não HDL e escore Gensini ou SYNTAX. Conclusões: Embora tenha havido discordância entre colesterol LDL e não-HDL (15% dos pacientes), não há diferença quanto à gravidade e complexidade da DAC entre os grupos discordantes e concordantes.


Subject(s)
Humans , Coronary Artery Disease , Retrospective Studies , Risk Factors , Coronary Angiography , Cholesterol, HDL , Cholesterol, LDL
SELECTION OF CITATIONS
SEARCH DETAIL